V. D. Dodge, E. M. Cox
Dodge & Cox Stock Fund
Dodge & Cox Stock Fund Portfolio 13F
Dodge & Cox Stock Fund Holdings Activity
- Portfolio value:
- $89.21B≈ (+$8B≈)
- Previous value:
- $81.11B≈
- # of changes:
- 47
- New positions:
- 0
- Reported for:
- 30 Jun 2021 (Q2)
- Latest filing date:
- 30 Aug 2021
Dodge & Cox Stock Fund has disclosed a total of 47 changes to the portfolio in the (2021 Q2) SEC report(s): increased the number of shares of 23, decreased the number of shares of 23 and completely sold out 1 position(s).
What stocks did Dodge & Cox Stock Fund buy in 2021 Q2?
During 2021 Q2 Dodge & Cox Stock Fund has bought 23 securities out of which top 5 purchases (by % change to portfolio) were (SNY) Sanofi ADR (added shares +2.04%), (GSK) GlaxoSmithKline PLC ADR (added shares +0.88%), (CHTR) Charter Communications Inc (added shares +1.52%), (RTX) RTX Corp (added shares +1.03%) and (BNY) BANK OF NEW YORK MELLON CORP (added shares +2.19%).
What did Dodge & Cox Stock Fund invest in during 2021 Q2?
47 results
| History | Ticker | Name |
% or activity |
Shares change |
Shares held after* |
% change to portfolio |
Reported price* |
% difference current price* |
% of portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
T-Mobile US Inc
|
+482.40%
|
+5,446,500
|
6,575,537
|
+0.88%
|
$144.83
|
+21.72%($176.28)
|
1.07%
|
2020 Q2
|
≈ 1.25 years
|
|
|
|
Honda Motor Co Ltd ADR
|
+274.01%
|
+19,649,218
|
26,820,200
|
+0.71%
|
$32.18
|
-7.77%($29.68)
|
0.97%
|
2021 Q1
|
≈ 0.50 years
|
|
|
|
Incyte Corp
|
+227.83%
|
+5,874,647
|
8,453,200
|
+0.55%
|
$84.13
|
+41.30%($118.88)
|
0.80%
|
2019 Q3
|
≈ 2.00 years
|
|
|
|
Gilead Sciences Inc
|
+60.81%
|
+7,360,000
|
19,463,212
|
+0.57%
|
$68.86
|
+88.00%($129.46)
|
1.50%
|
2019 Q3
|
≈ 2.00 years
|
|
|
|
Fiserv, Inc
|
+45.46%
|
+4,383,800
|
14,027,000
|
+0.53%
|
$106.89
|
-49.13%($54.38)
|
1.68%
|
2020 Q4
|
≈ 0.75 years
|
|
|
|
Cognizant Technology Solutions Corp, CL-A
|
+42.13%
|
+5,484,800
|
18,502,477
|
+0.43%
|
$69.26
|
-20.18%($55.28)
|
1.44%
|
2019 Q3
|
≈ 2.00 years
|
|
|
|
Alnylam Pharmaceuticals Inc
|
+28.84%
|
+695,985
|
3,109,177
|
+0.13%
|
$169.52
|
+27.67%($216.43)
|
0.59%
|
2019 Q3
|
≈ 2.00 years
|
|
|
|
Biomarin Pharmaceutical Inc
|
+26.41%
|
+1,770,142
|
8,471,425
|
+0.17%
|
$83.44
|
-28.16%($59.94)
|
0.79%
|
2019 Q4
|
≈ 1.75 years
|
|
|
|
Fox Corp, CL-B
|
+23.27%
|
+1,630,868
|
8,640,633
|
+0.06%
|
$35.20
|
+48.87%($52.40)
|
0.34%
|
2019 Q3
|
≈ 2.00 years
|
|
|
|
Cisco Systems Inc
|
+17.27%
|
+4,422,700
|
30,037,587
|
+0.26%
|
$53.00
|
+117.91%($115.49)
|
1.78%
|
2019 Q3
|
≈ 2.00 years
|
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.